Stockhead on MSN2d
AdAlta prioritises ‘East to West’ cellular immunotherapy strategy to drive value creationAdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.
Stockhead on MSN8d
AdAlta boosts leadership in Q2 FY25 to support growth strategyFY25 saw AdAlta (ASX:1AD) focus on increasing its corporate muscle, with two new board members and additional advisors ...
HotCopper.com on MSN2d
'East to West': AdAlta unveils new strategy to find drug candidates, but appears to've ditched AD-214AdAlta (ASX:1AD) has unveiled a new grand plan to take cell therapy candidates from Southeast Asia, firm them up in ...
TipRanks on MSN2d
AdAlta Limited Unveils Strategic ‘East to West’ Cellular Immunotherapy ApproachAdAlta Ltd. ( ($AU:1AD) ) just unveiled an announcement. AdAlta Limited is set to host an investor webinar to discuss its ‘East to West’ cellular ...
Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener AdAlta Ltd ...
Perform clinical stage drug discovery and developing next generation protein and cell-based therapeutics.
Perform clinical stage drug discovery and developing next generation protein and cell-based therapeutics.
The agreement was brokered by Adalta Energy and will deliver cost-savings of around 20% and will provide real-time data usage through the installation of advanced 15-minute meters, Reconomy said.
Index rose 3.20% in January as markets had a strong start to 2025 with the benchmark S&P/ASX 200 rising by 5% to reach a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback